NEW YORK — Avricore Health said on Thursday that it has signed a definitive agreement to provide rapid SARS-CoV-2 antigen testing for international travelers in partnership with Avrok Laboratories.
Last month, the companies signed a letter of intent that called for Avrok, which operates a CLIA-certified lab in California, to oversee the on-site testing of travelers in Canada, the US, Mexico, and the Caribbean. Test results would be reported directly via Avricore's HealthTab point-of-care screening and test result management platform.
The letter of intent included a revenue sharing agreement between the companies based on contracts secured with resorts, airlines, and other organizations engaged in SARS-CoV-2 travel testing.
Vancouver, British Columbia-based Avricore said that the companies have now finalized the arrangement. Additional terms were not disclosed.
"Transportation service providers and destinations around the world are as eager to resume normal travel activity as consumers are," Avricore CEO Hector Bremner said in a statement. "By offering real-time reporting and an API capable solution, we can meet the needs of the various stakeholders in terms of maintaining their portals for managing data, while making it easy for their travelling customers."